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lung toxicity did not correlate with lung V10. There was also 
no relationship between mean oesophageal dose/V35/V55 
and fistula or oesophageal stricture. Increase in PTV volume 
appeared to be significantly associated with grade of acute 
oesophagitis, but this trend was not observed when late 
oesophagitis or acute/late pneumonitis were examined. 
Conclusions: From our experience, IMRT to the thorax is well 
tolerated, with minimal grade 3 toxicity. Contrary to reports, 
we did not observe a correlation between lung V5 and 
acute/late lung toxicity however this data needs to be 
confirmed with a larger number of patients. Data will be 
updated prior to the ESTRO meeting. 
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Purpose/Objective: Current guidelines do not recommend 
the use of elective nodal irradiation for NSCLC, for several 
reasons. One of these is that PET-CT provides adequate 
mediastinal nodal staging; thus, the involved field 
radiotherapy is all the more justified. We present a 
systematic review that compared the published rates of 
elective nodal failures (ENFs), which were defined as regional 
failures that occur without simultaneous or previous local 
recurrence in patients who did or did not undergo PET-CT for 
staging. 
Materials and Methods: Reports of the occurrence of ENFs 
were considered. Only studies that used involved fields and 
specified the number of ENFs in patients with and without 
PET-CT use were included. A chi-squared test was used for 
the comparison of the risk of ENF in patients who were 
staged with and without PET. 
Results: In total, 65 studies that reported the occurrence of 
ENF after radiotherapy for NSCLC were found. Finally, 48 
studies were included and 2158 patients with and 1485 
patients without PET-CT performed before radiotherapy were 
identified. There were 136 (6.3%) and 98 (6.6%) ENFs in 
patients with and without PET-CT, respectively (p = .74). The 
proportion of patients who were treated with SBRT was 
higher in the group with PET-CT (71%) than it was in the 
group without PET-CT (20%; p < .001). In the group of 
patients who were treated with SBRT without PET-CT, there 
were 19 (6.5%) ENFs compared with 106 (6.9%) ENFs in SBRT 
patients with PET-CT (p = .82). After excluding patients who 
were treated with SBRT, we detected 79 ENFs (6.6%) in 1192 
patients without PET-CT, and 30 (4.9%) ENFs in 617 patients 
with PET-CT performed before radiotherapy (p=.16). 
Conclusions: The failure to reduce ENF by PET-CT was 
demonstrated. These data should be regarded in the context 
of the adequacy of reporting the rate of ENF and of the 
clinical relevance of the reported rates. 
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Purpose/Objective: To evaluate brachial plexus toxicity post 
stereotactic body radiation therapy (SBRT) of apically 
situated lung lesions. 
Materials and Methods: We retrospectively identified 41 
patients with 42 apically located tumors, defined as the 
epicenter located superiorly to the aortic arch, and treated 
with SBRT-technique. Median prescription dose per fraction 
was 15 Gy (6-17) and median number of fractions was 3 (3-
10). Primary aim was to evaluate radiation induced 
neurological symptoms defined as radiation induced brachial 
plexopathy and radiation induced upper extremity pain 
according to CTCAE v4.0. No patients had neurological 
extremity symptoms before the treatment.  
Results: Six patients experienced grade 2 (scored 4 times) 
and 3 (scored 4 times) neurologic toxicity after a median of 
9.4 months (4.0-19.1). Two patients had pain + sensory 
alterations, weakness and paralysis of the hand and/or arm, 
3 patients had pain only and 1 patient had sensory 
alterations, numbness and weakness of the arm. These 
patients had a median PTV volume of 84.0cc (51.3-142.0) and 
the median Dmax and D1cc to the plexus were 324.0 Gy (29.9-
523.7) and 83.2Gy (3.0-294.7) (BED3) respectively. All but one 
of these patients had ≤2mm between the PTV and the plexus. 
The patients without neurological symptoms had a median 
PTV-volume of 35cc (10.4-502.6) and the median Dmax and 
median D1cc to the plexus were 24.4 (0.2-483.2) and 3.8 Gy 
(0.1-264.5) (BED3) respectively. Interestingly, 11 patients 
(median follow-up 20.5 months) had Dmax >100Gy (BED3), but 
did not develop neurological symptoms. Median follow-up for 
the entire cohort was 30.1months (0.3-62.7). 
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Conclusions: SBRT of apically located lung lesions may cause 
severe neurological symptoms; Dmax and large PTV being risk 
factors. 
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Purpose/Objective: To determine if a weekly cone-beam CT 
(CBCT) is enough to evaluate the entire tumor inclusion and 
the reproducibility throughout the radiation course treatment 
in lung cancer. 
Materials and Methods: Thirty-six lung cancer patients were 
treated with image-guided radiotherapy (IGRT) on an Elekta 
Synergy Beam Modulator linear accelerator.  
The GTV included the tumor and the positive nodes in PET-CT 
and pathologic analysis. The PTV was configured with the 
GTV and a margin of 0.7 cm – 1 cm in all directions. 
In our protocol of lung cancer treatment, prior to each 
radiotherapy fraction we make one cone-beam CT every day 
on the first five days of treatment using automated soft-
tissue registration. The positional errors of the reference 
image in relation to the acquired image (given in terms of 
translation movements) were obtained. No rotations were 
permitted. The average of these translational movements in 
the three axes (x, y, z) was calculated. This average was 
applied from the sixth day of treatment until the end. 
Weekly image guidance was registered resulting in at least 10 
CBCT scans for each patient. The deviations in the three axes 
in every weekly CBCT with respect to the average were 
analyzed (Tx, Ty, Tz) 
Results: The graphics summarize the result of our analysis.  
 
 
In 29 patients (80.6%) the mean value of the difference 
between the positional errors compared to the average was: 
x = (0.19 ± 0.14) cm, y = (0.21 ± 0.14) cm, z = (0.27 ± 0.16) 
cm. All these values were less than 0.5cm and were 
considered correct for the suitable treatment of the patients. 
The shifts in the z axis showed more variability compared to 
the other axes mainly related to breathing movements. 
Nevertheless this z axis variability did not influence on the 
entire tumor inclusion and the set up reproducibility. 
In the other 7 patients (19.4%) we obtained a greater 
difference in either axes, and a CBCT more often than once a 
week was evaluated by the physician. 
Conclusions: Our preliminary results showed that in most 
lung cancer patients treated with IGRT, once an average is 
calculated after the first five days of treatment, a weekly 
cone-beam CT is enough to evaluate the entire tumor 
inclusion and the reproducibility throughout the radiation 
treatment.  
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Purpose/Objective: Lung cancer is responsible for 22% of 
cancer deaths annually. One factor which may contribute to 
reduced survival is treatment related toxicity. Whether the 
cardiotoxic effect of chemo-radiation may contribute to 
adverse outcome in lung cancer is uncertain. The aim of this 
pilot study is to use cardiac MRI to investigate cardiac muscle 
injury, function and cardiac biomarkers in patients being 
treated for non-small cell lung cancer (NSCLC).  
Materials and Methods: The study plans to recruit 20 
evaluable NSCLC patients. Study assessments are made on 4 
occasions: pre-treatment, during treatment, 6 weeks and 6 
months after treatment initiation. Evaluations include clinical 
assessment, cardiac MRI, ECG and serum cardiac biomarkers. 
